Human BCL10 (B-Cell Lymphoma/Leukemia 10) - Recombinant Protein
Beta LifeScience
SKU/CAT #: BLT-00300P
SDS-PAGE analysis of Human BCL10 (B-Cell Lymphoma/Leukemia 10) - Recombinant Protein, CAT# BLT-00300P, showing >95% purity under 15% SDS-PAGE (Reduced)
Human BCL10 (B-Cell Lymphoma/Leukemia 10) - Recombinant Protein
Beta LifeScience
SKU/CAT #: BLT-00300P
Regular price
$59500
$595.00
Sale price$54500
$545.00Save $50
/
Quantity Pricing
| Pack Size | Price (USD) |
|---|---|
| 500 µg | $1,375 |
| 1 mg | $2,245 |
For direct online orders, quantity pricing will be displayed in cart when you add 5x100ug or 10x100ug
Submit an inquiry or email inquiry@betalifesci.com for a customization request or bulk order quote.
Connect with us via the live chat in the bottom corner to receive immediate assistance.
Product Overview
| Product Name | Recombinant Human B-Cell CLL/Lymphoma 10 (Bcl10) Protein |
| Product Overview | This recombinant human B-Cell CLL/Lymphoma 10 (Bcl10) protein includes amino acids 1-233aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization. |
| Target Uniprot Id | O95999 |
| Recommended Name | B-cell lymphoma/leukemia 10 |
| Gene Name | BCL10 |
| Synonyms | B-cell lymphoma/leukemia 10, c-E10, CARMEN, CIPER, CLAP, mE10. |
| Species | Human |
| Predicted Molecular Mass | 30 kDa |
| Expression System | E.coli |
| Expression Range | 1-233aa |
| Tag | N-6His |
| Purity | >95% |
| Formulation | Lyophilized |
| Buffer | Phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose |
| Storage Condition | 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
| Reconstitution Instruction | Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
| Applications | Positive Control; Immunogen; SDS-PAGE; WB |
| Research Area | Apoptosis |
| Target Function | Plays a key role in both adaptive and innate immune signaling by bridging CARD domain-containing proteins to immune activation. Acts by channeling adaptive and innate immune signaling downstream of CARD domain-containing proteins CARD9, CARD11 and CARD14 to activate NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines. Recruited by activated CARD domain-containing proteins: homooligomerized CARD domain-containing proteins form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerization of BCL10, subsequent recruitment of MALT1 and formation of a CBM complex. This leads to activation of NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines. Activated by CARD9 downstream of C-type lectin receptors; CARD9-mediated signals are essential for antifungal immunity. Activated by CARD11 downstream of T-cell receptor (TCR) and B-cell receptor (BCR). Promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK. |
| Subcellular Location | Cytoplasm, perinuclear region. Membrane raft. |
| Associated Diseases | Immunodeficiency 37 (IMD37); Lymphoma, mucosa-associated lymphoid type (MALTOMA) |
| Tissue Specificity | Ubiquitous. |
